Narrative review / 2014
The intestinal microbiome is a potential therapeutic target in the development and treatment of cardio-metabolic diseases.
Recent studies suggest a potential role for intestinal microbes in the expression of certain human cardio-metabolic diseases. Mechanisms through which gut microbiota and their metabolic products affect systemic homeostasis and cardio-metabolic risks are beginning to be uncovered. Human intervention studies focused on altering microbial composition or pharmacologically manipulating microbiota to influence metabolite production are needed next steps.
- Study type
- Narrative review
- Who was studied
- Human cardio-metabolic disease contexts (review)
- What was measured
- Contribution of intestinal microbiota and metabolites to cardio-metabolic disease
THE PAPER
The gut microbiome as novel cardio-metabolic target: the time has come!
Vinjé S, Stroes E, Nieuwdorp M, Hazen SL. Eur Heart J, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.